Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 1.00 |
| ▸ | RAB9A | P51151 | 11/20 | 1.00 |
| ▸ | PKM | P14618 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.70 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.70 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.70 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MITF | O75030 | 1/20 | 0.62 |
| ▸ | XBP1 | P17861 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29083758 | 0.85 | NPC1 (0.74) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL16604283 | 0.84 | NPC1 (0.76) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL17675306 | 0.81 | NPC1 (0.72) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL16594545 | 0.80 | NPC1 (0.70) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL21349103 | 0.80 | NPC1 (0.70) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL26293792 | 0.80 | NPC1 (0.70) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL17065565 | 0.80 | NPC1 (0.89) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL2176413 | 0.80 | NPC1 (0.89) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL7900640 | 0.79 | NPC1 (0.68) | NPC1RAB9APKMSMN1; SMN2LMNA | |
| SCHEMBL14082359 | 0.78 | NPC1 (0.71) | NPC1RAB9APKMSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010111653-A2 | MODULATING IRES-MEDIATED TRANSLATION | THE UAB RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | EIF2AK2, EIF4EBP1, EIF4E | NPC1 2519/4885RAB9A 2106/4885PKM 3436/4885 |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | EIF2AK2, RPS25, RPL35 | NPC1 859/4885RAB9A 2752/4885PKM 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.